Version 2.78

Description

Certolizumab is a monoclonal antibody conjugated to polyethylene glycol used to treat Crohn's Disease (CD) and rheumatoid arthritis (RA). Certolizumab pegol binds to tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine that is implicated in the pathogenesis of a number of immunological diseases including CD and RA. TNFα mediates the signature inflammation-induced joint damage in RA. The reduction of TNFα alleviates symptoms of RA, CD and other immunologic diseases. TNFα-inhibitors have been hugely successful in treating immunological diseases. In spite of the positive impact TNFα-inhibitors have had there is still variability in response to their use including loss of response over time and drug tolerance. PMID: 20190560 Source: Regenstrief LOINC

Basic Part Properties

Part Display Name
Certolizumab
Part Type
Component (Describes the core component or analyte measured)
Created On
2017-05-09
Construct for LOINC Short Name
Certolizumab

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=LP250847-3

Language Variants Get Info

Tag Language Translation
it-IT Italian (Italy) Certolizumab pegol
Synonyms: Certolizumab pegolo
es-ES Spanish (Spain) Certolizumab
zh-CN Chinese (China) 塞妥珠单抗
Synonyms: 塞妥珠单克隆抗体;塞妥珠;Certolizumab 单抗
nl-NL Dutch (Netherlands) certolizumab